{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:50:17Z","timestamp":1789627817337,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04107-5","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T05:25:47Z","timestamp":1762061147000},"page":"1411-1421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Are conventional and hypofractionated chemoradiotherapy comparable in glioblastoma patients?"],"prefix":"10.1007","volume":"28","author":[{"given":"Fiorella Cristina","family":"Di Guglielmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria.","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Ciliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Gregucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Surgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Caliandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Giraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Surico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Annunziata","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Calbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Intern\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Laera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Talienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-5852","authenticated-orcid":false,"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"issue":"7","key":"4107_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329(7):574\u201387.","journal-title":"JAMA"},{"issue":"8","key":"4107_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol. 2020;22(8):1073\u2013113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106.","journal-title":"Neuro-Oncol"},{"issue":"6","key":"4107_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/jmri.29016","volume":"58","author":"YW Park","year":"2023","unstructured":"Park YW, Vollmuth P, Foltyn-Dumitru M, Sahm F, Choi KS, Park JE, et al. The 2021 WHO classification of tumors of the central nervous system: clinical implications. J Magn Reson Imaging. 2023;58(6):1680\u2013702.","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"4107_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4107_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7.","journal-title":"Lancet Oncol"},{"key":"4107_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol. 2012;13:916\u201326.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4107_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1611977.","journal-title":"N Engl J Med"},{"key":"4107_CR8","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","volume":"33","author":"W Roa","year":"2015","unstructured":"Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33:4145\u201350.","journal-title":"J Clin Oncol"},{"key":"4107_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00066-010-2101-x","volume":"186","author":"M Balducci","year":"2010","unstructured":"Balducci M, Apicella G, Manfrida S, Mangiola A, Fiorentino A, Azario L, et al. Single- arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high grade gliomas. Strahlenther Onkol. 2010;186:558\u201364.","journal-title":"Strahlenther Onkol"},{"key":"4107_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109663","volume":"184","author":"M Niyazi","year":"2023","unstructured":"Niyazi M, Andratschke N, Bendszus M, Chalmers AJ, Erridge SC, Galldiks N, et al. Estro-eano guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184:109663. https:\/\/doi.org\/10.1016\/j.radonc.2023.109663.","journal-title":"Radiother Oncol"},{"key":"4107_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0360-3016(98)00266-1","volume":"43","author":"SW Lee","year":"1999","unstructured":"Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43:79\u201388.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4107_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11547-017-0806-y","volume":"123","author":"S Scoccianti","year":"2018","unstructured":"Scoccianti S, Krengli M, Marrazzo L, Magrini SM, Detti B, Fusco V, et al. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiol Med. 2018;123:48\u201362.","journal-title":"Radiol Med"},{"key":"4107_CR13","first-page":"0217881","volume":"14","author":"PA Jablonska","year":"2019","unstructured":"Jablonska PA, Diez-Valle R, P\u00e9rez-Larraya JG, Moreno-Jim\u00e9nez M, Idoate M\u00c1, Arbea L, et al. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience. PLoS ONE. 2019;14:0217881.","journal-title":"PLoS ONE"},{"key":"4107_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/0300891618792483","volume":"105","author":"P Navarria","year":"2019","unstructured":"Navarria P, Pessina F, Cozzi L, Tomatis S, Reggiori G, Simonelli M, et al. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori. 2019;105:47\u201354.","journal-title":"Tumori"},{"key":"4107_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijrobp.2014.09.013","volume":"91","author":"G Minniti","year":"2015","unstructured":"Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys. 2015;91:109\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4107_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-019-03175-2","volume":"143","author":"S Pedretti","year":"2019","unstructured":"Pedretti S, Masini L, Turco E, Triggiani L, Krengli M, Meduri B, et al. Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. J Neurooncol. 2019;143:447\u201355.","journal-title":"J Neurooncol"},{"issue":"11","key":"4107_CR17","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/jpm11111145","volume":"11","author":"F Gregucci","year":"2021","unstructured":"Gregucci F, Surgo A, Bonaparte I, Laera L, Ciliberti MP, Carbonara R, et al. Poor-prognosis patients affected by glioblastoma: retrospective study of hypofractionated radiotherapy with simultaneous integrated boost and concurrent\/adjuvant temozolomide. J Pers Med. 2021;11(11):1145. https:\/\/doi.org\/10.3390\/jpm11111145.","journal-title":"J Pers Med"},{"issue":"12","key":"4107_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121351","volume":"11","author":"F Gregucci","year":"2021","unstructured":"Gregucci F, Bonaparte I, Surgo A, Caliandro M, Carbonara R, Ciliberti MP, et al. Brain linac-based radiation therapy: \u201cTest Drive\u201d of new immobilization solution and surface guided radiation therapy. J Pers Med. 2021;11(12):1351. https:\/\/doi.org\/10.3390\/jpm11121351.","journal-title":"J Pers Med"},{"key":"4107_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"4107_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02172-9","author":"F Gregucci","year":"2023","unstructured":"Gregucci F, Di Guglielmo FC, Surgo A, Carbonara R, Laera L, Ciliberti MP, et al. Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma. Strahlenther Onkol. 2023. https:\/\/doi.org\/10.1007\/s00066-023-02172-9.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"4107_CR21","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/jpm12081336","volume":"12","author":"F Gregucci","year":"2022","unstructured":"Gregucci F, Surgo A, Carbonara R, Laera L, Ciliberti MP, Gentile MA, et al. Radiosurgery and stereotactic brain radiotherapy with systemic therapy in recurrent high-grade gliomas: is it feasible? therapeutic strategies in recurrent high-grade gliomas. J Pers Med. 2022;12(8):1336. https:\/\/doi.org\/10.3390\/jpm12081336.","journal-title":"J Pers Med"},{"issue":"3","key":"4107_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2012.01.035","volume":"84","author":"K Reddy","year":"2012","unstructured":"Reddy K, Damek D, Gaspar LE, et al. Phase II trial of hypofractionated IMRT withtemozolomide for patients with newly diagnosed glioblastoma multiforme. IntJ Radiat Oncol Biol Phys. 2012;84(3):655-660.17.","journal-title":"IntJ Radiat Oncol Biol Phys"},{"issue":"4","key":"4107_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ijrobp.2010.07.021","volume":"81","author":"C Chen","year":"2011","unstructured":"Chen C, Damek D, Gaspar LE, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(4):1066-1074.18.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"4107_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","volume":"5","author":"MD Walker","year":"1979","unstructured":"Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationshipin the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725-1731.16.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4107_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ijrobp.2013.12.011","volume":"88","author":"T Iuchi","year":"2014","unstructured":"Iuchi T, Hatano K, Kodama T, et al. Phase 2 trial of hypofractionated high-dose intensity-modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2014;88(4):793-800.21.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"40","key":"4107_CR26","doi-asserted-by":"publisher","first-page":"67696","DOI":"10.18632\/oncotarget.18809","volume":"8","author":"P Navarria","year":"2017","unstructured":"Navarria P, Pessina F, Tomatis S, et al. Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. Oncotarget. 2017;8(40):67696\u2013708.","journal-title":"Oncotarget"},{"key":"4107_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.626400","volume":"10","author":"M Ferro","year":"2021","unstructured":"Ferro M, Ferro M, Macchia G, Cilla S, Buwenge M, Re A, et al. Post-operative accelerated-hypofractionated chemoradiation with volumetric modulated arc therapy and simultaneous integrated boost in glioblastoma: a phase I study (ISIDE-BT-2). Front Oncol. 2021;10:626400. https:\/\/doi.org\/10.3389\/fonc.2020.626400.","journal-title":"Front Oncol"},{"issue":"2020","key":"4107_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rpor.2020.08.010","volume":"25","author":"A Rayan","year":"2020","unstructured":"Rayan A, Abdel-Kareem S, Hasan H, Zahran AM, Gamal DA. Hypofractionated radiation therapy with temozolomide versus standard chemoradiation in patients with glioblastoma multiforme (GBM): A prospective, single-institution experience. Rep Pract Oncol Radiother. 2020;25(2020):890\u20138.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"2","key":"4107_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11060-010-0306-6","volume":"102","author":"M Terasaki","year":"2011","unstructured":"Terasaki M, Eto T, Nakashima S, et al. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol. 2011;102(2):247\u201353.","journal-title":"J Neurooncol"},{"key":"4107_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1200\/JCO.2008.18.9035","volume":"27","author":"DT Blumenthal","year":"2009","unstructured":"Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol. 2009;27:733\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.18.9035.","journal-title":"J Clin Oncol"},{"key":"4107_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noy017","volume":"20","author":"DT Blumenthal","year":"2018","unstructured":"Blumenthal DT, Won M, Mehta MP, Gilbert MR, Corn BW. Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology\/Radiation Therapy Oncology Group (RTOG) database. Neuro Oncol. 2018;20:1\u201326. https:\/\/doi.org\/10.1093\/neuonc\/noy017.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4107_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11060-018-2932-3","volume":"140","author":"S Mallick","year":"2018","unstructured":"Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, et al. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). J Neurooncol. 2018;140(1):75\u201382.","journal-title":"J Neurooncol"},{"issue":"1","key":"4107_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.radonc.2016.01.001","volume":"118","author":"G Louvel","year":"2016","unstructured":"Louvel G, Metellus P, Noel G, Peeters S, Guyotat J, Duntze J, et al. Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients. Radiother Oncol. 2016;118(1):9\u201315.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4107_CR34","first-page":"1","volume":"118","author":"L Lv","year":"2016","unstructured":"Lv L, Eda V, Callegaro-Filho S, Koch Lde D, Pontes Lde O, Weltman BE, et al. Minimizing the uncertainties regarding the effects of delaying radiotherapy for Glioblastoma: a systematic review and meta-analysis. Radiother Oncol. 2016;118(1):1\u20138.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4107_CR35","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1038\/s41598-020-66608-3","volume":"10","author":"I Zur","year":"2020","unstructured":"Zur I, Tzuk-Shina T, Guriel M, Eran A, Kaidar-Person O. Survival impact of the time gap between surgery and chemoradiotherapy in glioblastoma patients. Sci Rep. 2020;10(1):9595. https:\/\/doi.org\/10.1038\/s41598-020-66608-3.","journal-title":"Sci Rep"},{"issue":"1","key":"4107_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad086","volume":"5","author":"T Gupta","year":"2023","unstructured":"Gupta T, Selvarajan JMP, Kannan S, Menon N, Dasgupta A, Chatterjee A. Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma. Neuro-Oncol Adv. 2023;5(1):vdad086. https:\/\/doi.org\/10.1093\/noajnl\/vdad086.","journal-title":"Neuro-Oncol Adv"},{"issue":"10","key":"4107_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.6004\/jnccn.2015.0148","volume":"13","author":"LB Nabors","year":"2015","unstructured":"Nabors LB, Portnow J, Ammirati M, et al. Central nervous system cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(10):1191\u2013202.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"4107_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12101670","volume":"12","author":"N Gherasim-Morogai","year":"2022","unstructured":"Gherasim-Morogai N, Afrasanie VA, Gafton B, Marinca MV, Alexa-Stratulat T. Can extended chemotherapy improve glioblastoma outcomes?) a retrospective analysis of survival in real-world patients. J Pers Med. 2022;12(10):1670. https:\/\/doi.org\/10.3390\/jpm12101670.","journal-title":"J Pers Med"},{"issue":"5","key":"4107_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050428","volume":"15","author":"G Bonomo","year":"2025","unstructured":"Bonomo G, Certo F, Grasso E, Fiuman\u00f2 G, Barbagallo D, Caltabiano R, et al. Efficacy and safety of prolonged adjuvant temozolomide treatment in glioblastoma: prospective study of 81 patients undergoing up to 101 cycles of treatment. Brain Sci. 2025;15(5):428. https:\/\/doi.org\/10.3390\/brainsci15050428.","journal-title":"Brain Sci"},{"issue":"8","key":"4107_CR40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","volume":"19","author":"DT Blumenthal","year":"2017","unstructured":"Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG oncology\/RTOG. Neuro Oncol. 2017;19(8):1119\u201326. https:\/\/doi.org\/10.1093\/neuonc\/nox025.","journal-title":"Neuro Oncol"},{"issue":"18","key":"4107_CR41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","volume":"22","author":"C Balana","year":"2020","unstructured":"Balana C, Vaz MA, Manuel Sep\u00falveda J, Mesia C, Del Barco S, Pineda E, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14\u201301). Neuro Oncol. 2020;22(18):1851\u201361. https:\/\/doi.org\/10.1093\/neuonc\/noaa107.","journal-title":"Neuro Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04107-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:02:33Z","timestamp":1774414953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04107-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04107-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,2]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cThe authors declare no conflicts of interest.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following the Declaration of Helsinki, and approved by the Department Review Board (Title: Registro della Radioterapia Avanzata in Ambito Oncologico e Non: Advanced Radiotherapy study ARTs) of General Regional Hospital F. Miulli (protocol code ARTs 10\/2025) for studies involving humans.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"\u201cInformed consent was obtained from all subjects involved in the study.\u201d \u201cWritten informed consent has been obtained from the patient(s) to publish this paper\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}